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Limited duration of transgene expression, insertional muta-
genesis, and size limitations for transgene cassettes pose chal-
lenges and risk factors for many gene therapy vectors. Here,
we report on physiological expression of liver phenylalanine
hydroxylase (PAH) by delivery of naked DNA/minicircle
(MC)-based vectors for correction of homozygous enu2 mice,
a model of human phenylketonuria (PKU). BecauseMC vectors
lack a deﬁned size limit, we constructed aMC vector expressing
a codon-optimized murine Pah cDNA that includes a trun-
cated intron and is under the transcriptional control of a
3.6-kb native Pah promoter/enhancer sequence. This vector,
delivered via hydrodynamic injection, yielded therapeutic liver
PAH activity and sustained correction of blood phenylalanine
comparable to viral or synthetic liver promoters. Therapeutic
efﬁcacy was seen with vector copy numbers of <1 vector genome
per diploid hepatocyte genome and was achieved at a vector
dose that was signiﬁcantly lowered. Partial hepatectomy and
subsequent liver regeneration was associated with >95% loss
of vector genomes and PAH activity in liver, demonstrating
that MC vectors had not integrated into the liver genome. In
conclusion, MC vectors, which do not have a deﬁned size-
limitation, offer a favorable safety proﬁle for hepatic gene ther-
apy due to their non-integration in combination with native
promoters.
INTRODUCTION
Phenylketonuria (PKU; OMIM 261600) is an inborn error of meta-
bolism caused by deﬁciency of hepatic phenylalanine hydroxylase
(PAH; EC 1.14.16.1) due to autosomal recessively inheritedmutations
in the Pah gene. PAH catalyzes the conversion of L-phenylalanine
(L-Phe) to L-tyrosine using molecular oxygen and the cofactor tetra-
hydrobiopterin.1 In the absence of liver PAH activity, L-Phe accumu-
lates in blood and other tissues causing damage to the developing
brain, but the liver itself is unaffected by PAH deﬁciency. PKU in
humans comprises a clinical continuum of elevated blood L-Phe
concentrations with levels up to 600 mmol/L on an unrestricted
diet, commonly classiﬁed as mild hyperphenylalaninemia, between
600–1,200 mmol/L as mild PKU, and those over 1,200 mmol/L as
classic PKU (normal blood L-Phe = 50–100 mmol/L) with the degree
of L-Phe elevation correlating generally to the speciﬁc Pah genotype
of the patient. Contemporary therapy for classical PKU is based on
dietary L-Phe restriction; however, future treatments may include
enzyme substitution with enteral or parenteral administration of
the bacterial enzyme phenylalanine ammonia lyase or gene
augmentation therapy using viral or non-viral vector systems to target
liver or other organs (for more details see Blau et al.1 and Thöny2).
The Pahenu2/enu2 mouse, a model of human PKU, faithfully replicates
the physiological and behavioral abnormalities associated with
untreated human patients, including hyperphenylalaninemia, hypo-
pigmentation, growth retardation, maternal PKU syndrome, and
cognitive deﬁcits.3 We (and others) have used this model of human
PKU extensively in the past to study various aspects of this metabolic
disease and for development of novel therapies including gene
therapy.
Gene therapy has great potential for treatment of many inherited
disorders by directly addressing the genetic defect, and several recent
treatment successes have been reported.4 Development of novel gene
transfer vectors that direct tissue-speciﬁc, persistent, and high levels
of transgene expression but with minimal toxicity from anti-vector
immune responses or insertional mutagenesis remains an important
objective. Vectors that do not integrate into the host genome have the
advantage of low toxicity and avoidance of potential germline trans-
mission but at the same time may fail to produce long-term therapeu-
tic efﬁcacy in mitotically active tissues because of gradual loss of vec-
tor DNA and transgene expression. For liver-directed gene therapy,
the most advanced or promising vector system today is recombinant
adeno-associated virus (AAV) that has yielded mixed success for
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therapy of hemophilia in ongoing clinical trials.4 Some of the remain-
ing challenges for clinical use of recombinant AAV are the require-
ment for high (and expensive) vector doses, the limited cargo capacity
for an expression cassette, the non-persistent expression due to im-
mune-mediated vector elimination, the inability to (re)administer
the vector due to anti-capsid antibody, and the repeatedly observed
oncogenic potential for insertional mutagenesis and development of
hepatocellular carcinomas in mice.5,6 It is thus a vital aspect for the
success of liver-directed gene therapy to develop vector systems
that allow persistent and safe expression. We are exploring potential
alternative vector systems to AAV for liver gene therapy and have
previously reported on long-term safe and efﬁcacious treatment of
PKU mice through delivery of non-viral naked minicircle DNA
(MC-DNA)-vectors via a single hydrodynamic tail vein injection
without adverse effects.7 The MC-DNA vectors employed in that
study was entirely devoid of any bacterial or viral sequences and
only contained a minimal expression cassette that expressed the
mouse Pah-cDNA from a synthetic liver promoter (P3). While deliv-
ery of naked DNA is still challenging, and for liver-targeting currently
only possible in an experimental setting with mice or pigs (by hydro-
dynamic injections), the MC vector system has great potential and
avoids most of the problems related to viral vectors (for a broader dis-
cussion see Yin et al.,8 Gaspar et al.,9 and Stoller et al.10).
In the present study, we aimed to further characterize and improve
the MC-DNA vectors for gene therapy of murine PKU as a model
for a genetic liver defect. Experimental studies included in vivo testing
for episomal maintenance of MC vectors, codon-optimization, addi-
tion of a 50-intron, and expression under potentially “physiological”
conditions from its endogenous Pah promoter. The latter may have
several advantages, as use of the endogenous promoter restricts trans-
gene expression to liver thereby helping to avoid potential immuno-
genicity of the transgene product and also likely reduces the copy
number of vector genomes per cell necessary for persistent, long-
term physiologically relevant expression. Although the use of tis-
sue-speciﬁc promoters has been the central focus for the development
of gene therapy vectors (for a review, see Toscano et al.11), the choice
of natural or endogenous promoters was hampered by limited
genome size capacity in AAV vectors. The lack of any deﬁned genome
size limit forMC vectors has allowed us to study liver PAH expression
from a gene transfer vector that utilized the endogenous Pah pro-
moter. We found that the use of the native promoter, along with
codon-optimization and inclusion of a truncated intron in the
cDNA, lead to robust, long-term liver PAH expression in PKU
mice, and we concluded that MC vectors have an overall favorable
safety proﬁle for therapy of genetic liver defects.
RESULTS
Loss of Episomal MC Vector and PAH Activity after Partial
Hepatectomy and Liver Regeneration in MC-Treated PKU Mice
MCs are considered to be passively maintained as non-integrating
(and non-replicating) vectors and thus bear little risk for insertional
mutagenesis. To investigate whether MCs in our vector-treated
PKU mice remained episomal and thus subject to elimination
following hepatocyte turnover, we performed partial hepatectomy
(pHx) and examined untreated (control) versus MC-treated mice
before and after liver regeneration. Past experience has shown that
the restoration of liver PAH activity to only 5% of wild-type activ-
ity was sufﬁcient to maintain blood L-Phe levels below a deﬁned
therapeutic level (%360 mmol/L). We have previously shown that
hydrodynamic tail vein injection of 3 1013 copies of MC.PKU20 ex-
pressing mPah-cDNA under control of the synthetic liver-speciﬁc
promoter (P3) was sufﬁcient to persistently lower the blood L-Phe
level in PKU mice.7 Here, we injected ﬁve PKU mice with vector
MC.PKU37 (3 1013 particles) that is identical to vector MC.PKU20
except for expressing an N-terminally Flag-tagged PAH. As depicted
in Figure 1A and Table 1, untreated PKU mice remained hyperphe-
nylalaninemic (L-Phe >1,200 mmol/L) while blood L-Phe levels
decreased to below the therapeutic level of 360 mmol/L in MC-treated
PKUmice. Twenty-eight days after gene delivery, pHx removing two-
thirds of the liver was performed (see Figure S2). As indicated by the
ratio of liver/body weight in Table 1, livers regenerated to the original
mass,12 and concomitantly, blood L-Phe levels in MC-treated mice
increased back up to 1,219 ± 328 mmol/L (for all ﬁve mice) that
was similar to L-Phe levels in control animals (1,315 mmol/L) or to
pre-treatment levels in MC-treated mice. Liver tissue from three
treated mice (and control) was collected for molecular analysis
by pHx at day 28 and again at euthanasia (day 49). As shown in
Table 1, pHx in MC-treated mice resulted in a >95% loss of PAH
enzyme activity (i.e., from 58% ± 36% down to 2.3% ± 2.3% compared
to wild-type) and 95% loss of vector copy number per hepatocyte
(i.e., from 86.6 ± 38.5 copies to 4.5 ± 4.0 copies). The loss ofMC-DNA
was further conﬁrmed by histological examination where we found
17.7% ± 8.1% positively stained hepatocytes expressing Flag-PAH
protein mouse liver at pHx while there were only 1.9% ± 0.4% posi-
tively stained cells 3 weeks after pHx (Figures 1B–1F, respectively).
The one-tailed p value of t test for Flag-positive cell counting in Fig-
ure 1B was not signiﬁcant due to the large variation of the number of
positive hepatocytes between the two mice analyzed. H&E staining
illustrated that no liver damage or necrosis was observed during the
entire experiment (Figures 1G and 1H). The re-rise of blood L-Phe
levels to pre-treatment values, concomitant with the loss of MC-DNA
and hepatic PAH expression in MC-treated mice, conﬁrms that MC
vectors do not integrate into the genome but rather are maintained as
episomes that corroborates our previous observations from Southern
blot analyses7 (see also Discussion).
Expression of PAH from Its Native Endogenous Pah Promoter-
Enhancer Corrects Hyperphenylalaninemia
A 10-kb fragment upstream of the mouse Pah gene has initially been
characterized in in vitro studies to harbor the essential liver-speciﬁc
promoter elements for PAH expression, including four DnaseI hyper-
sensitive sites (HSSI-HSSIV).13–15 Further reﬁnement revealed that
the critical sites for liver expression can be narrowed down within a
transcription-start upstream-fragment comprising the hypersensitive
sites HSSI to HSSIII, including the full HSSIII enhancer site corre-
sponding to a liver-speciﬁc and hormone-inducible enhancer that
was localized within a 410-bp fragment between kb 3.5 and 3.2
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(Figure 2A).13 Based on these observations, we ampliﬁed the entire
3.6 kb 50-fragment including part of exon 1 from mouse genomic
DNA and placed it in frame upstream of themPah-cDNA to generate
MC.PKU43 (for more details see the Supplemental Materials and
Methods and Figure S1). This so-called P6 promoter-enhancer was
tested for liver (and kidney)-speciﬁc expression of PAH activity
from an MC vector. PKU mice were injected with 3  1013 copies
of MC.PKU43 via tail vein and euthanized 80 days later for organ
collection. We detected PAH enzyme activity exclusively in liver
with 12% ± 3% of wild-type (Table 2).
Next, we performed a dose-escalation study in PKU mice to test for
the minimal amount of vector required for therapeutic efﬁcacy of
the P6 promoter-enhancer construct. For comparison, we used iden-
tical MC vectors expressing the mPah either from the synthetic liver
promoter P3 (MC.PKU20) or the classical “modiﬁed cytomegalovirus
(CMV) enhancer/chicken b-actin” (CBA) promoter (MC.PKU38).
The latter was also used in our earlier AAV-vector-based liver-
directed gene therapy experiments to correct PKU in mice.16,17
Various doses of all three vectors were infused via hydrodynamic
tail vein injection for delivery to hepatocytes, followed by monitoring
blood L-Phe level over a period of 80 days until euthanasia. As illus-
trated in Figures 2B–2D and Table 2, we found that the therapeutic
threshold for all three MC vectors was a dosage of 6  1012 copies
per injection as this resulted in blood L-Phe levels below the deﬁned
therapeutic threshold of 360 mmol/L over the entire therapy period of
80 days. Lower amounts of injected DNA vector also resulted in a
sharp response by lowering the high blood L-Phe but to a level still
considered to be (mildly) hyperphenylalaninemic. On euthanasia,
we found 1.3–8.1 MC vector genomes per diploid hepatocyte genome
and 7%–13% liver PAH activity for all vectors at a dose of 6  1012
copies. Based on the observation that only 18% of all hepatocytes
of a mouse liver are transduced with MC-DNA (see Figure 1B and
Viecelli et al.7), it can be calculated that between 8–47 copies of
MC-DNA were present per transduced (diploid) hepatocyte.
The similar outcome for these three vectors was somewhat surprising
as we infused the same number of vector copies but each vector was
considerably different in total size so that 6 1012 copies were equiv-
alent to DNA doses of 15.4 mg, 25.2 mg, and 38.6 mg total DNA admin-
istered for vector MC.PKU20 (2.1 kb), MC.PKU38 (3.5 kb), and
MC.PKU43 (5.5 kb), respectively. From this observation, we conclude
that MC vector copy number administered rather than the total DNA
amount is the more important dosing parameter. Furthermore, we
Figure 1. MC Vectors Are Maintained as Episomes and Are Lost during Hepatocyte Turnover
(A) Five PKU mice were treated with 3  1013 copies of vector MC.PKU37 expressing the Flag-tagged PAH. At day 28, two-thirds of the mouse liver were removed and
3 weeks later, after liver regeneration, mice were sacrificed (at day 49). For control, two untreated PKU mice were included for pHx. Blood L-Phe levels were followed and
depicted as themean ±SD. (B–H) Livers from two of the fiveMC.PKU37-treatedmice shown in (A) were processed for histological analyses. (B) Mean ±SDwas calculated for
the percentage of Flag-positively stained cells from five random fields in 2.5magnification of each mouse. (C–F) Histology of liver sections that were stained with anti-Flag
antibody followed by hematoxylin counterstaining. Representative examples of a random field in 2.5 and 10 magnifications after liver resection at day 28 (C and E) and
3 weeks after pHx (D and F). Histological examination of liver sections after H&E staining (G) at pHx (day 28) and (H) 21 days after surgery (day 49).
www.moleculartherapy.org
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did not observe any sex-dependent difference in therapeutic efﬁcacy
(for L-Phe levels, PAH enzyme activity, and copy number per
hepatocytes).
We continued to monitor a few MC-treated mice beyond 80 days
post injection in order to evaluate long-term effects including mice
treated with MC.PKU38 followed out to 179 days, 339 days for
MC.PKU43, and up to 353 days for MC.PKU20. Blood L-Phe levels
(not shown) remained either below the therapeutic threshold or
were mildly hyperphenylalaninemic at the time point of euthanasia
(Table 2). Overall, our data demonstrate robust and life-long liver
PAH expression and therapeutic efﬁcacy following treatment with
MC vector containing the native P6 promoter-enhancer. In conclu-
sion, MC vectors that have no deﬁned size limitations can express
their therapeutic transgene from a large endogenous or natural pro-
moter-enhancer element with comparable efﬁciency like synthetic or
viral promoters commonly used for expression from gene therapeutic
vectors with limited cargo capacity. Overall, our data showed that
regarding expression of PAH and therapeutic efﬁcacy, the natural
endogenous P6 promoter-enhancer revealed robust and life-long
performance.
Codon-Optimization and Inclusion of an Intron Fragment in the
Pah-cDNA Improves Therapeutic Efficacy at Significantly
Reduced MC Vector Dosage
In a next step, we aimed to further improve the mouse Pah-cDNA
expression cassette of vector MC.PKU20 through codon-opti-
mization (mcoPah) and inclusion of a 50 intervening sequence.
While the design of codon optimization is done with support
from computational methods, we also validated efﬁcient splicing
of the artiﬁcial intron in vitro and in vivo. We chose to evaluate
a truncated version of Pah intron 1 as the entire IVS-1 of the
mouse Pah gene is 6.2 kb long. Our ﬁrst construct that included
a so-called fragment IVS-1A was not efﬁciently spliced (as tested
in vitro; see the Supplemental Information). In a second attempt,
IVS-1B, which retains 300 bp from the 50 end and 520 bp from
the 30 end of Pah IVIS1 but lacks 5.4 kb from the native intron,
was introduced between exons 1 and 2 in the Pah cDNA. The
combined alterations of codon-optimization and intron inclusion
resulted in vector MC.PKU28 (Figure 3A; see Supplemental Mate-
rials and Methods and Figure S1 for further details). Hydrody-
namic injection into PKU mice and subsequent liver cDNA
analysis revealed correct splicing from vector MC.PKU28 (Fig-
ure 3B). Next, we injected PKU mice with different doses of
MC.PKU28 and analyzed treatment performance over a period
of 80 days and in comparison with MC.PKU20. We found that
therapeutic correction of blood L-Phe was achieved with injection
of 6  1011 MC.PKU28 copies, a dose that is 10-fold lower
than that needed to achieve efﬁcacy with MC.PKU20 (Figure 3A;
Table 2). A further decrease in dose down to 3  1011 copies of
MC.PKU28 still yielded a clear response in lowering the blood
L-Phe levels; however, this dose did not achieve the therapeutic
threshold of 360 mmol/L blood L-Phe. Nevertheless, excellent
long-term performance of vector MC.PKU28 was further demon-
strated by a single mouse injected with 3  1013 vector copies
and remained at normal blood L-Phe levels for a period of
414 days (see Table 2).
We again measured the MC-DNA copy number remaining in liver
after the treatment period of 80 days. Mice that had received
6 1011 vector copies of MC.PKU28 and had exhibited a robust ther-
apeutic response retained on average 0.3 ± 0.1 copies per diploid
genome in liver. Successful treatment with MC.PKU20 required a
10-fold higher vector dose and yielded 9 ± 4.3 copies of MC.PKU20
per diploid liver genome 80 days after injection. The ﬁnding of ther-
apeutic efﬁcacy with a 10-fold lower vector copy number retained in
liver is in agreement with the results from the vector-titration studies
and thus conﬁrms that our codon-optimized intron containing vec-
tor MC.PKU28 is superior to the parental MC-vector. Assuming
again that 18% of all hepatocytes were transduced, 1.8 copies of
MC.PKU28 are statistically present per transduced diploid hepatocyte
that is a value close to having two functional native Pah alleles (see
Discussion).
Finally, we investigated the performance of vector MC.PKU44 that
harbors the mcoPah-IVS-1B expression cassette under transcription
control of the endogenous promoter-enhancer P6. The results are
depicted in Figure 3C and Table 2. We found that injections between
3–6  1011 copies of MC.PKU44 per animal was therapeutic and
yielded 0.5–1 vector copy number per diploid genome in liver
80 days after injection. These results were similar to those for vector
MC.PKU28 (see also Figure 4).
Table 1. Liver Analysis of Treated PKU Mice after pHx
Mouse and Treatment pHx (No. of Mice)
PAH Enzyme
Activity (% of WT) Blood L-Phe (mmol/L)
DNA Copy Number Per
Diploid Genome
Ratio Liver/
Body Weight
PKU, untreated
before day 28 (n = 1) <0.2 1,383 NA ND
after day 49 (n = 1) <0.2 1,315 NA 2.9
PKU, MC.PKU37-treated
before day 28 (n = 3) 58 ± 36 70 ± 18 86.6 ± 38.5 ND
after day 49 (n = 3) 2.3 ± 2.3 1,227 ± 386 4.5 ± 4.0 4.3 ± 0.18
Two untreated PKU mice were used as control, one for histological staining and the other one for molecular analysis, while ﬁve PKU mice were treated with 3  1013 copies of vector
MC.PKU37 (77 mg) expressing the Flag-tagged PAH under control of the synthetic liver-speciﬁc promoter P3. The resected liver lobes from three mice were collected before pHx (day
28) and after liver regeneration (day 49) for various analyses, including PAH activity, blood L-Phe levels, vector copy number per diploid genome, and as a mass of regeneration the
ratio of liver-over-body weight. pHx, partial hepatectomy; NA, not applicable; ND, not determined; WT, wild-type.
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MC-DNA Vector Prepared by an Ultra-Pure versus Standard
DNA Purification Method Had No Influence on the Efficacy of
L-Phe Clearance in Mouse Liver
We previously reported that MC vector puriﬁcation using a research
grade DNA isolation kit yielded 97% pure MC-DNA with very
minor contamination of parental plasmid, bacterial backbone, and/or
bacterial chromosomal DNA.7 To date, we have prepared all MC-
DNA vectors for injection from bacterial cultures using commercially
available endotoxin free DNA puriﬁcation kits that utilize a classic
alkaline lysis approach followed by anion-exchange resin column
(see the Supplemental Materials and Methods). Although we had
no indication for inﬂammatory or immune-stimulatory effects in
MC-treated mice whatsoever,7 we examined whether more highly
puriﬁed18 MC-DNA, prepared using PlasmidFactory’s (PF) afﬁnity
chromatography-based MC production technology (see the Supple-
mental Materials andMethods), would exhibit better therapeutic per-
formance. As displayed in Figures S3A and S3B, standard kit grade
MC.PKU28 DNA demonstrated that most of the MC DNA was
present as a monomeric covalently closed circular (ccc) supercoiled
molecule, but a signiﬁcant amount was relaxed open circular mono-
mer, dimer, trimmer, tetra-, and larger concatemers. In contrast,
more than 98% of highly puriﬁedMC.PKU28 (PF) was in monomeric
supercoiled ccc form with undetectable bacterial chromosomal DNA
or bacterial endotoxin (see Figures S3C and S3D). The behavior of
research (kit) grade versus highly puriﬁed MC-DNA was investigated
through administration of MC.PKU20 and MC.PKU28 vectors to
PKU mice where we found basically no difference in outcomes
regardless of the MC-DNA puriﬁcation method used (see Table 2).
DISCUSSION
The main novel ﬁndings of the present study are the observation that
MC vectors are maintained in episomal state in vivo, and a native pro-
moter sequence in combination with an optimized expression cassette
MC.PKU38 (3.5 kb)
MC.PKU43 (5.5 kb)
MC.PKU20 (2.1 kb)
HSSI
+1
HSSII
-1.3 kb
HSSIII
-3.2 kb-3.5 kb
~ 3.6 kb P6
HSSI, II and III: DNase I-hypersensitive site 
3 x 1013 copies (n = 6)
6 x 1012 copies (n = 3)
3 x 1012 copies (n = 3)
3 x 1013 copies (n = 4)
6 x 1012 copies (n = 4)
3 x 1012 copies (n = 4)
3 x 1013 copies (n = 9)
6 x 1012 copies (n = 3)
3 x 1012 copies (n = 4)
A B
C D
**
**
*
*
Figure 2. Physiological Expression and Thus Correction of Hyperphenylalaninemia in PKU Mice after Delivery of an MC-DNA Vector Driving Expressing of
Pah by Its Natural Liver Promoter-Enhancer
(A) Schematic of the 3.6 kbmurine Pah genomic promoter-enhancer fragment, termed P6, which was amplified and inserted intoMC.PKU20 to replace the P3 promotor. The
P6 promotor contains the coding part of exon 1 (open box), the 50 untranslated region (striped box) and the 3.5-kb fragment upstream of 50 untranslated region (gray box)
including three DNase I-hypersensitive sites (HSSI, HSSII, and HSSIII). (B–D) Comparison of blood L-Phe level in PKU mice treated with three different vectors expressing
mPah by different promoters, i.e., (B) endogenous mouse Pah promoter-enhancer P6, (C) modified cytomegalovirus enhancer/chicken b-actin (CBA) promoter, and
(D) the synthetic liver promoter P3. PKUmice were infused with three different doses of MC-vectors, 3 1013, 6 1012, and 3 1012. Note that in (D) data frommice treated
with 3 1013 and 3 1012 copies, but not with 6 1012 copies of vector MC.PKU20, were taken from a previous publication and are shown for comparison.7 Serum L-Phe
levels in treated mice injected with 6  1012 and 3  1012 copies of different MC-DNA vectors in (B)–(D) were compared for statistically significant difference by one-tailed
Student’s t test at days 4, 21, and 80 following vector administration.
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can yield physiologically relevant PAH expression in Pahenu2/enu2
mice, a model of human PKU. We have previously demonstrated
through Southern blot analysis that MC-DNA does not integrate
into liver genomic DNA.7 Here, we employed pHx in MC-treated
mice to induce rapid hepatocyte turnover and observed a R95%
loss of MC-DNA and PAH activity. This result corroborates that
MC-DNA is maintained as a non-integrated and non-replicating vec-
tor in vivo. Using similar approaches, evidence for episomal mainte-
nance of plasmids19,20 or S/MAR-containing MC vectors has been
previously reported;21 however, to our knowledge, this has never
been convincingly demonstrated directly for MC vectors lacking
S/MAR elements in mice that were corrected by gene therapy. Never-
theless, complete exclusion of MC vector integration at a very low fre-
quency needs further proof using more sophisticated methods than
Southern blot or pHx. Non-integrating gene transfer vectors lack
any signiﬁcant risk of (random) insertional mutagenesis. Concerns
regarding low level insertional mutagenesis and consequent hepatic
malignancy have been raised even for recombinant AAV vectors,
which are considered to be nonpathogenic and non-integrating.22
On the other hand, gradual vector genome loss with normal hepato-
cyte turnover is a potential disadvantage of any vector system that re-
lies on maintenance of episomes. This has not been a limitation for
MC-DNA, as vector DNA (as well as silenced parental plasmid
DNA) has been persistent in adult mouse liver out to at least 1 year
following vector injection (see Table 2 and Viecelli et al.7). Presum-
ably, administration of MC to newborn animals would not yield sta-
ble therapeutic correction as MC episomes would be rapidly elimi-
nated with normal hepatocyte proliferation. However, even if MC
Table 2. Liver Analysis of Treated PKU Mice Sacrificed at Different Time Points following Gene Delivery
MC Vector Treatment
(Size of Vector)
MC Vector Dosage: No. of
Particles (mg of MC-DNA)
Time Point on Sacriﬁcation
(No. of Mice)
PAH Enzyme
Activity (% of WT)
Blood L-Phe
(mmol/L)
DNA Copy Number
Per Diploid Genome
Wild-type, untreated NA (n = 5) 100 53 ± 7 NA
PKU, untreated NA (n = 5) <0.3 1,683 ± 245 NA
MC.PKU20 (2.1 kb)a
3  1013 (77)
3  1013 (77)
6  1012 (15.4)
3  1012 (7.7)
3  1012 (7.7)
day 52 (n = 1)
day 179 (n = 2)
day 80 (n = 3)
day 10 (n = 1)
day 353 (n = 3)
15
9 ± 8
11 ± 10
3
2 ± 0
150
205 ± 66
272 ± 287
532
464 ± 172
3.5
2.5 ± 0.7
4.9 ± 4.3
1.5
2.6 ± 0.8
MC.PKU20 (PF) (2.3 kb)
3  1012 (8.2)
3  1011 (0.8)
day 80 (n = 2)
day 15 (n = 2)
3 ± 0
3 ± 1
470 ± 245
1,265 ± 1
6.8 ± 0.2
2.3 ± 1.2
MC.PKU28 (2.8 kb)
3  1013 (100)
3  1013 (100)
3  1013 (100)
3  1012 (10)
6  1011 (2)
3  1011 (1)
3  1011 (1)
day 48 (n = 1)
day 80 (n = 2)
day 414 (n = 1)
day 80 (n = 3)
day 80 (n = 3)
day 21 (n = 1)
day 80 (n = 2)
22
47 ± 2
10
15 ± 7
3 ± 1
2
3 ± 1
144
74 ± 11
127
79 ± 9
178 ± 59
1,680
1,097 ± 190
1.7
2.9 ± 1.8
0.9
3.2 ± 0.4
0.3 ± 0.1
0.3
0.1 ± 0
MC.PKU28 (3.0 kb)
3  1012 (10.5)
3  1011 (1)
day 80 (n = 3)
day 80 (n = 2)
23 ± 6
2 ± 0
72 ± 3
889 ± 287
12.7 ± 5.3
1.2 ± 0.7
MC.PKU38 (3.5 kb)
3  1013 (126)
3  1013 (126)
6  1012 (25.2)
3  1012 (12.6)
day 80 (n = 3)
day 179 (n = 3)
day 80 (n = 3)
day 80 (n = 3)
25 ± 16
12 ± 2
13 ± 4
5 ± 3
130 ± 73
103 ± 14
235 ± 174
644 ± 539
1.4 ± 0.8
5.5 ± 2.1
1.3 ± 0.4
1.0 ± 0.5
MC.PKU43 (5.5 kb)
3  1013 (193)
3  1013 (193)
6  1012 (38.6)
3  1012 (19.3)
3  1012 (19.3)
day 80 (n = 4)
day 339 (n = 1)
day 80 (n = 4)
day 32 (n = 2)
day 80 (n = 2)
12 ± 3
2
7 ± 5
1 ± 1
3 ± 0
191 ± 105
609
213 ± 125
443 ± 244
454 ± 131
8.5 ± 4.3
2.8
8.1 ± 6.4
3.2 ± 2.1
0.9 ± 0.8
MC.PKU44 (6.1 kb)
3  1012 (21.7)
6  1011 (4.3)
3  1011 (2.2)
day 80 (n = 3)
day 80 (n = 5)
day 80 (n = 4)
9 ± 2
2 ± 1
1 ± 1
186 ± 132
475 ± 152
761 ± 258
1.0 ± 0.2
0.5 ± 0.4
0.2 ± 0.1
PAH enzyme activity and copy numbers of vector genomes in whole liver extracts of PKUmice infused with various MC-DNA vectors and different doses were analyzed. Blood L-Phe
levels correspond to time of sacriﬁcation. Note that L-Phe values during whole treatment periods are shown in Figures 1 and 2. The type and size of each construct, vector dosage, time
point of euthanasia and the numbers of mice analyzed, and DNA copy numbers per diploid hepatocyte genome are indicated. Details of each construct are depicted in Figure S1. In
brief, MC.PKU20 harbors the synthetic liver-speciﬁc promoter P3 and Pah-cDNA, MC.PKU28 a codon-optimized mouse Pah (mcoPah) and a truncated intervening sequence 1B
(IVS-1B) driven by P3, MC.PKU38 the modiﬁed cytomegalovirus (CMV) enhancer/chicken b-actin promoter (CBA) and Pah-cDNA,MC.PKU43 the endogenous promoter-enhancer
P6 and Pah-cDNA, and MC.PKU44 promotor P6, mcoPah and IVS-1B. PF: performance of high-quality puriﬁed MC-DNA vectors MC.PKU20 (PF) and MC.PKU28 (PF). NA, not
applicable; WT, wild-type.
aExcept for vector dose 6  1012, results from MC.PKU20 were taken from a previous publication (see Viecelli et al.7) for comparison. Note that 3  1013 MC-vector copies of
MC.PKU20 injected into an adult mouse (25 g) is equivalent to 1.2  1015 copies/kg.
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episomes are gradually lost from liver in adult mice, MC vectors, un-
like viral vectors, can be readministered.23
Application of vectors that use native mammalian promoters to drive
prolonged therapeutic transgene expression has broad potential in the
ﬁeld of gene therapy. Native promoters such as the human a1 anti-
trypsin (hAAT)24 or albumin promoter,25 as well as chimeric pro-
moters, including the apolipoprotein E (Apo E) enhancer/hAAT pro-
moters26 or the synthetic mammalian liver-speciﬁc promoter P3,7,27
have been used in both viral and non-viral vectors to successfully
target liver. Constructs that incorporate regulatory elements from
native promoters, for example low-density lipoprotein receptor
(LDLR),28 the Rpe65 and vitelliform macular dystrophy 2,29 and
the CD40L,30 have achieved restricted expression (for review, see
also Toscano et al.11), and expressing of the therapeutic protein driven
by the endogenous promoter in Wiskott-Aldrich syndrome patients
has shown a remarkable success.31 Use of endogenous regulatory se-
quences likely insures tissue-speciﬁc and physiologically relevant
therapeutic gene expression. In the case of treatment for PKU, intro-
duction of two vector genomes per hepatocyte of a vector expressing
the PAH cDNA from the PAH promoter replicates the natural state
of biallelic PAH expression from the endogenous Pah genes. As
described in the Results, we chose to test the 3.6 kb murine Pah
gene-upstream promoter-enhancer element that harbors the HSSIII
regulatory enhancer element and contains multiple protein binding
sites, including sites for ubiquitous factors (NF1 and AP1) as well
as for liver-enriched transcription factors hepatocyte nuclear factor
1 (HNF1) and CCAAT/enhancer binding protein (C/EBP).13 HNF1
is a major regulatory element involved in PAH expression as it has
been shown that the Pah gene fails to be expressed in HNF1a-deﬁ-
cient mice.32 Following administration of our constructs MC.PKU43
and MC.PKU44, which include the native Pah regulatory elements,
we detected PAH expression only in liver. Because hydrodynamic
tail vein injection restricts MC-DNA delivery essentially to liver
only,7 we cannot know from our experiment whether liver-restricted
PAH expression is due to the vector delivery method or to the use of
the endogenous liver-speciﬁc promoter sequence. Nevertheless, we
showed that a 3.6-kb sequence of upstream genomic DNA was sufﬁ-
cient to confer therapeutic sustained transgene expression in PKU
mice. Analysis of promoter performance demonstrated that blood
L-Phe levels dropped below the therapeutic level at day 4 of treatment
in the mice treated with MC-DNA vectors containing either the syn-
thetic P3 (MC.PKU20) or the hybrid CBA promoter (MC.PKU38). In
contrast, the L-Phe levels in mice receiving MC vectors expressing
PAH from the P6 promoter in vector MC.PKU43 declined gradually
and reached the same therapeutic level like the other promoters only
after 11 days (Figure 2). The reason for that is unclear, although it has
also been observed by others that the luciferase expression driven by a
native human vitelliform macular dystrophy 2 promoter was lower
initially compared to other viral promoters, but the activity gradually
increased and sustained for a few months.29 Overall, future therapeu-
tic development of MC-DNA vectors is attractive due the lack of vec-
tor size limitations that allows the incorporation of larger therapeutic
transgenes and native promoter that direct long-term physiologic
gene expression.
Gene expression is modulated at many levels, including transcription,
post-transcriptional RNA modiﬁcation (RNA splicing and export),
RNA stability, and ﬁnally mRNA translation. One important strategy
to improve in vivo protein expression from a therapeutic transgene is
to adjust codon usage to the codon preference of highly expressed host
genes (reviewed in Gustafsson et al.33) and furthermore to optimize
GC content. Computational algorithms that consider mRNA stability,
but reduce mRNA secondary structure and eliminate repetitive
A
B
C Figure 3. Inclusion of a Truncated IVS-1B in
CombinationwithPah-Codon-Optimization Allowed
a 10-Fold Reduction of Vector Dosage to Treat PKU
(A) Vector MC.PKU28 harboring an intron-containing
(IVS-1B) and codon optimization mouse mcoPah trans-
gene under the control of promoter P3 was injected
hydrodynamically into PKU mice at four different doses
(i.e., 3  1013, 3  1012, 6  1011, and 3  1011 vector
copies). (B) Gene expression (cDNA) analysis shows
correct splicing of mcoPah-IVS-1B in mouse liver treated
with MC.PKU28. The expected lengths of potential
non-spliced (2,142 bp) and correctly spliced (1,292 bp)
cDNA-fragments are indicated. (C) Vector MC.PKU44
was generated by replacing P3 with the endogenous Pah
promoter-enhancer P6 (see text). A dose-escalation study
to treat PKU mice was done with 3  1012, 6  1011, and
3  1011 vector copies per infusion. Blood L-Phe was
followed and depicted as the mean ± SD. Serum L-Phe
levels in treated mice injected with 6  1011 and 3  1011
copies of different MC-DNA vectors in (A) and (C) were
compared for statistically significant difference by one-
tailed Student’s t test at day 4, 21, and 80 following vector
administration.
www.moleculartherapy.org
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elements andCpG islands,34 are available for planning optimization of
codon usage, and many reported studies have illustrated that trans-
gene expression can be dramatically improved through codon optimi-
zation.35–37 For example, a study by Wang and colleagues38 demon-
strated 100-fold and 33-fold improvements in protein production
and enzyme activity, respectively, following codon optimization of a
humanornithine transcarbamylase (OTC) cDNA to achieve therapeu-
tic effects at lower vector doses. Several ongoing human clinical trials
for clotting factor IX deﬁciency (hemophilia B) have utilized similar
codon optimization strategies.39–41 Codon optimization of our mouse
Pah-cDNA resulted in alteration to 20% of the base pairs in the
native coding sequence (for details see the Supplemental Materials
andMethods). Changes in codon usage were combined with insertion
of a 850 bp-truncated IVS-1B intron fragment between exon 1 and
exon 2. This strategy was based on a classic report by Palmiter
et al.42 demonstrating that inclusion of theﬁrst intron of the rat growth
hormone gene was essential for high-level expression in transgenic
systems. It was speculated that the ﬁrst intron was particularly impor-
tant because it was close to the transcriptional start site, and because
the optimal sequence for attachment of the translational machinery
might extend into the ﬁrst intron. Splicing from promoter proximal
introns has been shown to enhance transcription,43 while splicing of
terminal introns has been shown to increase the efﬁciency of polyade-
nylation.44 The process of splicing might enhance mRNA stability in
the nucleus or lead to more efﬁcient transport into the cytoplasm,45,46
resulting in greater accumulation of mature mRNA in the cytoplasm.
Also, intronic sequences may protect pre-mRNA from degradation.47
Taken together, all these data suggest that the combination of trans-
gene codon optimization along with the incorporation of introns
may signiﬁcantly increase expression. The genome size limitations
inherent to most gene transfer vectors preclude inclusion of all native
introns of a therapeutic gene. As there is no genome size limit in MC
vectors, it would have been possible to include the entire 6-kb inter-
vening sequence 1 of Pah in an MC vector. However, construction
of a mini-intron by removing regions that were not essential for
splicing has also been shown to yield correct protein-dependent
splicing.48Moreover, a study from Jallat et al.49 reported that including
a 1.4-kb truncated fragment of the ﬁrst intron of human factor IX into
the expression cassette of transgenic mice produced much higher pro-
tein expression than a similar construct containing only the cDNAand
demonstrated that the entire intervening sequence 1 was not neces-
sary. We evaluated dose-dependent treatment efﬁcacy only from a
MC vector that included both codon optimization and inclusion of
IVS-1B in combination. Our study showed that this optimized trans-
gene yielded therapeutic efﬁcacy at a dose (6  1011 vector copies per
mouse) that was 10-fold lower than the dose required for the parental
MC.PKU20 vector, which included the native Pah cDNA and lacked
an intron (Figures 3A and 4; Table 2).
In conclusion, our study demonstrates that MC vectors have a favor-
able safety proﬁle, including negligible liver toxicity or evidence of
inﬂammation following hydrodynamic delivery (see Kattenhorn
et al.6) and direct long-term, persistent therapeutic gene expression
despite their non-integrating nature. The lack of a vector genome
size limit allows the combined insertion of generally larger natural
promoter-enhancer elements and intron sequences. A combination
of these improvements will beneﬁt the development of non-viral
MC vectors for the treatment genetic liver defects.
MATERIALS AND METHODS
Gene Delivery and Animal Experiments
All animal experiments were approved by the State Veterinary Ofﬁce
of Zurich and were carried out according to the guidelines of the
Swiss Law of Animal Protection, the Swiss Federal Act onAnimal Pro-
tection (1978), and the Swiss Animal Protection Ordinance (1981).
Young adult (7–12 weeks old; 16–22 g) female and male homozygous
C57BL/6-Pahenu2/enu2 (“PKU”) mice were used for all experiments.
Mice were maintained on standard chow and only for L-Phe determi-
nation, food was withdrawn 3–4 hr prior to tail vein bleeding. Blood
was collected from tail veins onGuthrieﬁlter cards, and L-Phe concen-
tration was determined using tandem mass spectrometry. Minicircle
Figure 4. Summary of In Vivo Performance of MC
Vector Constructs at Therapeutic Doses
Data in this graph were compiled from Figures 2 and 3, as
well as from Table 2. The therapeutic MC-vector doses (i.e.,
number of particles injected) are given on the left side.
Therapy was defined as blood L-Phe levels at 360 mmol/L
or below. Treated mice were sacrificed 80 days after MC
vector injection for liver analyses to determine PAH enzyme
activity and DNA copy number per diploid genome, which
are given on the right side. Note that the vector size be-
tween the two most effective constructs, MC.PKU28 and
MC.PKU44, differ considerable due to different promoter
fragments and may thus not be directly comparable (see
also Discussion).
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(MC)-DNA vectors at the indicated doses were infused into mice for
liver targeting by hydrodynamic tail vein injection as described.7
Vector Construction and MC Production
Six out of eight MC-producer plasmids with various expression
cassettes were constructed according to the description in the
Supplemental Materials and Methods that included pMC.PKU20,
pMC.PKU28, pMC.PKU37, pMC.PKU38, pMC.PKU43, and
pMC.PKU44 (Figure S1). After transforming the MC-producer plas-
mids into E. coli ZYCY10P3S2T, corresponding MC vectors were
generated and puriﬁed by using the QIAGEN endofree plasmid puri-
ﬁcation kit (QIAGEN AG) as previously described7 and analyzed by
agarose gel electrophoresis (example shown in Figure S3A) and/or
capillary gel electrophoresis (CGE) (Figure S3C). More details of all
expression cassettes and quality control are described in the Supple-
mental Materials and Methods.
Partial Hepatectomy
PKU mice that were either infused with saline as a negative control
group or treated with vector MC.PKU37 expressing the Flag-tagged
phenylalanine hydroxylase (PAH) (Viecelli et al.7, also see Vector
Construction and MC Production). Blood was collected periodically
from tail veins to determine the L-Phe concentration. On day 28,
all treated mice received standard 70% pHx. In brief, a midline inci-
sion was performed and the liver freed from ligaments. The pedicle of
the caudate and left lobe was ligated (silk, 6/0) and resected as shown
in Figure S2. After cholecystectomy (Prolene, 8/0), the middle lobe
was ligated in two steps (silk 6/0) and resected. The resected lobes
were either ﬁxed in 4% formalin for immunohistochemistry staining
or snap-frozen for further molecular analysis. Vascular and biliary
structures of the right anterior and posterior lobe were preserved by
this technique and visually controlled. Three weeks after pHx (on
day 49), mice were sacriﬁced and livers were collected for either
immunohistochemistry staining or molecular analysis.
PAH Enzyme Assay
PAH enzyme activity in whole liver extracts was measured according
to a highly sensitive and quantitative assay using isotope-dilution
liquid chromatography-electrospray ionization tandem mass spec-
trometry (LC-ESI-MS/MS, API 4000, Sciex) developed in our labora-
tory.50 Frozen tissues were lysed at +4C in homogenization buffer as
described51 using a QIAGEN TissueLyser device (QIAGEN AG) ac-
cording to our published method.50
RT-PCR for Liver cDNA Analysis of Correct Splicing
A total of 20–30 mg of mouse liver tissue was used for total RNA isola-
tion using QIAmp RNA blood mini kit (QIAGEN AG) in accordance
with themanufacturer’s protocol. Randomprimed cDNAwas prepared
from 1 mg of total RNA using the Reverse Transcription kit (Promega).
PCRampliﬁcationof the cDNAfromexon 1 to exon 13ofmcoPah (vec-
tor MC.PKU28) was performed using the primers forward 50-CATG
GCAGCTGTTGTCCTGGAG-30 and reverse 50-GCCCACTT
CGCTGTTGATGGAG-30. The ampliﬁed product was separated by
agarose gel electrophoresis, extracted using NucleoSpin Gel and PCR
clean-up (Macherey-Nagel), and analyzed by Sanger sequencing with
the same forward and reverse primers (expected size of product was
1,292 bp if IVS-1B was correctly spliced, or 2,142 bp if the truncated
intron IVS-1B was retained). Quantiﬁcation of copy number by real-
time qPCR is described in the Supplemental Materials and Methods.
Histological Studies
Flag-tagging was required for histochemical analysis to discriminate
between the transgenic minicircle-derived wild-type PAH and the
endogenous mutant PAH-p.Phe263Ser expressed from the enu2 allele
in PKU mice, as the (inactive) mutant protein is highly expressed in
PKU (see also Viecelli et al.7). In brief, mouse livers were perfused
through hepatic portal vein with 4% PBS-buffered paraformaldehyde.
Subsequently, the organs were ﬁxated with 10% formalin and pre-
served in ethanol 70% for parafﬁn embedding. The specimens were
sectioned into 3-mm thick slices and stained with H&E for regular
histo-pathological analysis. For immunohistochemistry, the primary
DYKDDDDK tag antibody (1:500–1:1,000, cat #2368, Cell Signaling
Technology) diluted in TBST-5% normal goat serum was used.
The sections were then incubated with anti-rabbit SignalStain
Boost Detection Reagent (cat #8114, Cell Signaling Technology) for
30 min at room temperature. The slides were stained using liquid
DAB Substrate Chromogen (DAKO North America) and hematoxy-
lin for counterstain. Sections were examined and images were taken at
2.5- and 10-fold magniﬁcations using a Leica microscope and camera
(Leica UTR 6000). The assessment of the Flag-tag was analyzed by a
publicly available web application, called ImmunoRatio, which calcu-
lates the percentage of positively diaminobenzidine (DAB)-stained
area out of the total hematoxylin-stained nuclear areas.52
More materials and methods are described in the Supplemental Ma-
terials and Methods.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Materials and
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